home · filing · 0001493152-24-038339
8-K filed September 26, 2024, 7:59 PM ET
ticker PRPH
CIK 0000868278
leadership
confidence high
sentiment negative
materiality 0.55
ProPhase Labs director Eleanor McBrier resigns; Nasdaq audit committee vacancy triggers non-compliance cure period
ProPhase Labs, Inc.
Eleanor McBrier resigned as director effective Sep 20, 2024 due to conflict with employer policies; no dispute with company.
Vacancy on audit committee caused non-compliance with Nasdaq Listing Rule 5605(c)(2)(A).
Nasdaq confirmed non-compliance on Sep 26; cure period ends earlier of next annual meeting or Sep 20, 2025.
Company plans to regain compliance and is searching for a replacement with gastroenterology focus for BE-Smart test.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Departed
Eleanor McBrier
director
PRPH ·
ProPhase Labs, Inc.
Effective 2024-09-20
Filed September 26, 2024, 7:59 PM ET
On September 20, 2024, Eleanor McBrier notified the Board of her intention to resign as director of the Company, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Eleanor McBrier resigned as director at ProPhase Labs, Inc..
Action resigned
Role director
Exact text from the filing
On September 20, 2024, Eleanor McBrier notified the Board of her intention to resign as director of the Company, effective immediately.
View on SEC.gov
Source: SEC EDGAR
accession 0001493152-24-038339
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.